HRP20100210T1 - Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala - Google Patents

Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala Download PDF

Info

Publication number
HRP20100210T1
HRP20100210T1 HR20100210T HRP20100210T HRP20100210T1 HR P20100210 T1 HRP20100210 T1 HR P20100210T1 HR 20100210 T HR20100210 T HR 20100210T HR P20100210 T HRP20100210 T HR P20100210T HR P20100210 T1 HRP20100210 T1 HR P20100210T1
Authority
HR
Croatia
Prior art keywords
allopurinol
erythrodysesthesia
treatment
intended
caused
Prior art date
Application number
HR20100210T
Other languages
English (en)
Croatian (hr)
Inventor
Rodemer Yolanda
Original Assignee
Nobera Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06011432A external-priority patent/EP1862166A1/en
Application filed by Nobera Pharma filed Critical Nobera Pharma
Publication of HRP20100210T1 publication Critical patent/HRP20100210T1/hr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/16Emollients or protectives, e.g. against radiation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HR20100210T 2006-06-01 2010-04-14 Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala HRP20100210T1 (hr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06011432A EP1862166A1 (en) 2006-06-01 2006-06-01 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia
EP07107744 2007-05-08
PCT/EP2007/055367 WO2007138103A1 (en) 2006-06-01 2007-05-31 Use of allopurinol for the treatment of palmar plantar erythrodysesthesia

Publications (1)

Publication Number Publication Date
HRP20100210T1 true HRP20100210T1 (hr) 2010-05-31

Family

ID=38512579

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20100210T HRP20100210T1 (hr) 2006-06-01 2010-04-14 Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala

Country Status (21)

Country Link
US (3) US7973046B2 (es)
EP (1) EP2035006B1 (es)
JP (3) JP5028480B2 (es)
KR (1) KR101471022B1 (es)
AT (1) ATE457729T1 (es)
AU (1) AU2007267069B2 (es)
CA (1) CA2654270C (es)
CY (1) CY1110336T1 (es)
DE (1) DE602007004849D1 (es)
DK (1) DK2035006T3 (es)
ES (1) ES2341379T3 (es)
HR (1) HRP20100210T1 (es)
IL (1) IL195472A (es)
MX (1) MX2008015266A (es)
NZ (1) NZ573248A (es)
PL (1) PL2035006T3 (es)
PT (1) PT2035006E (es)
RS (1) RS51252B (es)
RU (1) RU2438673C2 (es)
SI (1) SI2035006T1 (es)
WO (1) WO2007138103A1 (es)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2246057A1 (en) * 2009-04-29 2010-11-03 Nobera Pharma, S.L. Use of allopurinol for the treatment of hand foot skin reaction
CN102648279B (zh) 2009-10-16 2015-11-25 杜克大学 用于治疗药物诱发的手足综合征的组合物与方法
EP2368549A1 (en) 2010-03-25 2011-09-28 BioAlliance Pharma Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
JP4761000B1 (ja) * 2010-11-08 2011-08-31 小野薬品工業株式会社 手足症候群の予防および/または治療剤
JP4983989B2 (ja) * 2010-03-31 2012-07-25 小野薬品工業株式会社 手足症候群の予防および治療剤
EP2554184B1 (en) * 2010-03-31 2016-10-26 ONO Pharmaceutical Co., Ltd. Preventive and/or remedy for hand and foot syndrome
US9259343B2 (en) 2012-07-06 2016-02-16 Newman Technologies LLC Device for mitigating plantar fasciitis
EP2712613B1 (en) * 2012-09-28 2017-02-08 Pharmadab d.o.o. Vitamin K1 and uses thereof
JP2019512536A (ja) * 2016-03-28 2019-05-16 ヴィダック ファーマ リミテッド 局所投与のための安定な医薬組成物およびその使用
TW201927292A (zh) 2017-12-13 2019-07-16 大陸商上海小午醫藥科技有限公司 一種用於預防或治療與egfr被抑制相關疾病的方法
CN113975264A (zh) 2018-04-16 2022-01-28 上海岸阔医药科技有限公司 预防或治疗肿瘤疗法副作用的方法
RU2722396C2 (ru) * 2018-07-11 2020-05-29 Федеральное государственное бюджетное учреждение дополнительного профессионального образования "Центральная государственная медицинская академия" Управления делами Президента Российской Федерации (ФГБУ ДПО "ЦГМА") Способ лечения пальмарно-плантарной эритродизестезии

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3011A (en) * 1843-03-21 Improvement in water-wheels
EP0278040B1 (de) 1987-02-13 1991-08-14 Pharm-Allergan Gmbh Verwendung von Pteridinen und/oder Purinen oder eines Xanthinoxidase-Hemmers zur Herstellung eines Arzneimittels zur Behandlung von genetisch bedingten degenerativen Netzhauterkrankungen
JPH03106817A (ja) 1989-09-20 1991-05-07 Nippon Kayaku Co Ltd アロプリノール製剤
JPH066700A (ja) 1992-06-22 1994-01-14 Fujitsu General Ltd ハイビジョン受像機
GB9218711D0 (en) 1992-09-04 1992-10-21 Salim Aws S M Skin cancer treatment
AU4974893A (en) 1992-09-04 1994-03-29 Aws Shakir Mustafa Salim Skin treatment compositions containing dimethylsulphone and allopurinol or oxypurinol
JP3106817B2 (ja) 1993-11-02 2000-11-06 富士電機株式会社 漏電遮断器
US6284234B1 (en) * 1998-08-04 2001-09-04 Johnson & Johnson Consumer Companies, Inc. Topical delivery systems for active agents
US6060083A (en) 1999-04-01 2000-05-09 Topical Technologies, Inc. Topical DMSO treatment for palmar-plantar erythrodysethesia
AU2001267533A1 (en) * 2000-06-20 2002-01-02 Henkel Kommanditgesellschaft Auf Aktien Structure-improving hair care agents
ATE316786T1 (de) 2000-11-22 2006-02-15 Rxkinetix Inc Behandlung von mukositis
US7544348B2 (en) 2001-02-15 2009-06-09 Access Pharmaceuticals, Inc. Liquid formulations for the prevention and treatment of mucosal diseases and disorders
DK1455888T3 (da) * 2001-08-29 2009-08-24 Pharmakodex Ltd Topisk indgivelsesindretning
EP1461033B1 (en) * 2001-11-29 2013-02-27 Sound Pharmaceuticals Incorporated Methods and compositions for ameliorating the undesirable effects of chemotherapy
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
US6979688B2 (en) 2002-02-12 2005-12-27 Ford John P Treatment method against side-effects of chemotherapy
US20040214215A1 (en) * 2003-03-07 2004-10-28 Yu Ruey J. Bioavailability and improved delivery of alkaline pharmaceutical drugs
JP2007501865A (ja) 2003-06-11 2007-02-01 ノバセア インコーポレイティッド 放射線治療薬および放射線治療と併用した、活性ビタミンd化合物による癌の治療法
CA2528378A1 (en) 2003-06-11 2004-12-23 Novacea, Inc. Treatment of immune-mediated disorders with active vitamin d compounds alone or in combination with other therapeutic agents
US20050148908A1 (en) 2003-12-24 2005-07-07 Gregory Skover Apparatus containing a receiving element for treatment of skin
WO2005084301A2 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
JP4405326B2 (ja) 2004-06-28 2010-01-27 株式会社東芝 ランドリー機器
EP1791535B1 (en) * 2004-09-17 2008-07-30 BioMAS Ltd. Novel tellurium compounds and their use as immunomodulators

Also Published As

Publication number Publication date
NZ573248A (en) 2011-01-28
CY1110336T1 (el) 2015-01-14
US20140011820A1 (en) 2014-01-09
PL2035006T3 (pl) 2010-07-30
DE602007004849D1 (de) 2010-04-01
IL195472A0 (en) 2011-08-01
ES2341379T3 (es) 2010-06-18
RU2438673C2 (ru) 2012-01-10
PT2035006E (pt) 2010-04-22
US8557829B2 (en) 2013-10-15
RS51252B (sr) 2010-12-31
AU2007267069A1 (en) 2007-12-06
ATE457729T1 (de) 2010-03-15
JP2012180370A (ja) 2012-09-20
US20110224237A1 (en) 2011-09-15
RU2008152341A (ru) 2010-07-20
AU2007267069B2 (en) 2011-08-11
IL195472A (en) 2012-04-30
JP2014028851A (ja) 2014-02-13
EP2035006B1 (en) 2010-02-17
KR101471022B1 (ko) 2014-12-09
JP5389980B2 (ja) 2014-01-15
CA2654270A1 (en) 2007-12-06
CA2654270C (en) 2014-05-13
JP5028480B2 (ja) 2012-09-19
US20090306097A1 (en) 2009-12-10
JP2009542581A (ja) 2009-12-03
DK2035006T3 (da) 2010-04-19
MX2008015266A (es) 2009-02-10
EP2035006A1 (en) 2009-03-18
SI2035006T1 (sl) 2010-04-30
US7973046B2 (en) 2011-07-05
WO2007138103A1 (en) 2007-12-06
KR20090031697A (ko) 2009-03-27

Similar Documents

Publication Publication Date Title
HRP20100210T1 (hr) Upotreba alopurinola u liječenju eritrodisestezije dlana i stopala
JP2009542581A5 (es)
BRPI1014433A2 (pt) "derivado de um composto ou um sal farmaceuticamente aceitável, composição farmacêutica ou nutracêutica, e métodos para tratar uma condição, para reduzir o desenvolvimento à tolerância a medicamentos vasodilatadores, para estimular a função mitocondrial em células, para melhorar a estrutura ou a função muscular em um animal e os efeitos mitocondriais associados com exercício em um animal, para intensificar a capacidade de exercício em um animal, a saúde e a função muscular, e a recuperação de músculos de atividade vigorosa ou do dano associado com atividade vigorosa ou sustentada em um animal, e, usos de epicatequina ou um derivado de epicatequina, de nicorandil ou um derivado de nicorandil e suas combinações."
JP2010525050A5 (es)
BR0207024A (pt) Medicamento com ação inicial rápida para o tratamento de disfunção sexual
HRP20120798T1 (hr) Kappa-opijatni agonisti za lijeäśenje dijareja-predominantnog i naizmjeniäśnog sindroma iritabilnog crijeva
HRP20150375T1 (hr) Derivati piridazinona
JP2014516942A5 (es)
JP2013511534A5 (es)
BRPI0513673B8 (pt) método para produzir um medicamento para aumentar a eficácia e o transporte dos compostos biologicamente ativos enteralmente administrados, e composição farmacêutica
WO2007064448A3 (en) Cancer treatment using fts and 2-deoxyglucose
HRP20192246T1 (hr) Marker za poremećaje kisele sfingomijelinaze i njegova uporaba
US20170333463A1 (en) Compositions and formulations of glucosamine for transdermal and transmucosal administration
AU2020278236A8 (en) Methods of treating Sjögren's Syndrome using a Bruton's tyrosine kinase inhibitor
JP2016505050A5 (es)
RU2011148355A (ru) Применение аллопуринола для ладонно-родошвенного синдрома
AR033390A1 (es) Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
Tubridy et al. Which drugs are most effective for recurrent herpes labialis?
JP2012525358A5 (es)
HRP20231448T1 (hr) Primjena delgocitiniba za liječenje kroničnog ekcema ruku
HRP20110127T1 (hr) Aksomadol za liječenje kod artritisa
BRPI0918593A2 (pt) composição farmacêutica para uso no tratamento de infecções transmitidas sexualmente
CN102058699B (zh) 一种治疗尘肺的药物
JP2017511307A5 (es)
JP2012530709A5 (es)